Loading clinical trials...
Loading clinical trials...
Curious to see if there is a sweet treat that doesn't spike your blood sugar (avoiding the energy crash, inflammation, and weight gain)? This study uses the Abbott Lingo CGM to see how your blood glucose levels responds to YES Bar-an all natural, gluten-free, plant-based bar that tastes like dessert. You'll track your levels before and after eating it to see if it fits into your metabolic health. (iOS Only)
This remotely administered decentralized trial is designed to rigorously evaluate the impact of Yes Bar on blood sugar levels in a real-world setting, utilizing the latest in continuous glucose monitoring technology provided by Abbott's Lingo CGM. The founder of Yes Bar initiated this study in response to numerous anecdotal reports suggesting that Yes Bar does not cause the blood sugar spikes typically associated with snack consumption. The objective is to move beyond these anecdotal experiences to gather solid, data-driven evidence regarding the metabolic effects of consuming Yes Bar. Participants in this study will engage in a unique and personal exploration of their metabolic health by tracking their blood sugar levels in response to consuming Yes Bars. Utilizing the Abbott Lingo CGM, which currently is compatible only with the iPhone, participants will monitor their blood glucose response, enabling an individualized assessment of how Yes Bar integrates into their dietary habits and metabolic health. This study is not solely for the purpose of marketing Yes Bars but aims to contribute valuable insights for participants themselves, providing them with concrete data on how their bodies respond to Yes Bars. By participating in at least four individual experiments with Yes Bar over a period of 7 days, participants will not only contribute to a broader understanding of the snack's metabolic impact but will also receive a $17 gift card as a token of appreciation for their contribution to this scientific inquiry. The primary goal of this trial is to scientifically assess the blood sugar response following the consumption of Yes Bar, leveraging the capabilities of the Abbott Lingo CGM. This endeavor also seeks to evaluate the feasibility of using consumer-grade continuous blood glucose monitors in dietary impact studies, in collaboration with Efforia. Through this study, we aim to bridge the gap between anecdotal evidence and empirical data, potentially transforming the way Yes Bar is marketed and perceived in the context of a healthy diet. This study is not only pivotal for marketing strategies but, more importantly, serves as an opportunity for participants to gain insights into their own metabolic health, offering a personalized perspective on how Yes Bar might help in avoiding the undesirable blood sugar fluctuations that lead to energy crashes and cravings. Participants will emerge from this study with personalized data that could inform their dietary choices and perhaps introduce them to a new, metabolically friendly snack option.
Age
All ages
Sex
ALL
Healthy Volunteers
Yes
Efforia
New York, New York, United States
Start Date
August 25, 2025
Primary Completion Date
August 25, 2026
Completion Date
August 25, 2026
Last Updated
December 26, 2025
100
ESTIMATED participants
YES Bar
OTHER
Lead Sponsor
Efforia, Inc
NCT06717646
NCT02296372
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions